We are using cookies to implement functions like login, shopping cart or language selection for this website. Furthermore we use Google Analytics to create anonymized statistical reports of the usage which creates Cookies too. You will find more information in our privacy policy.
OK, I agree I do not want Google Analytics-Cookies
International Poster Journal of Dentistry and Oral Medicine
Login:
username:

password:

Plattform:

Forgotten password?

Registration

Int Poster J Dent Oral Med 4 (2002), No. 1     15. Mar. 2002
Int Poster J Dent Oral Med 4 (2002), No. 1  (15.03.2002)

Poster 112, Language: English


A Phase II Trial of Concurrent Paclitaxel, Carboplatin and Radiotherapy in Stage III/IV Resectable Cancer of the Oral Cavity and Oropharynx
Küttner, Christian/Eckardt, André/Rades, D./Wildfang, Ingeborg/Hofele, Christof/Dammer, Ralf
Objective: Based on documented excellent radiosensitization effects, a prospective phase II trial was initiated using paclitaxel (P) and carboplatin (C) with concurrent conventional fractionated radiotherapy followed by surgery of the primary tumor and regional neck nodes.
Methods: From 6/98 - 8/99 twenty-eight patients (pts) received 5 cycles of weekly P (40mg/m2), C (AUC 1.5) with conventional radiotherapy 40Gy. Surgery was performed within 3-4-weeks after chemoradiation.
Results: Pts characteristics: 23 males, 5 females, mean age 54 (range 40-71); stage III 6, stage IV 22. Site: oropharynx 6, oral cavity 22. Twenty-seven pts were evaluable for toxicity and response. One early death was reported due to septic neutropenia. Clinical response was as follows: CR (14/27 52%); PR (13/27 48%). Twenty-three pts were evaluable for pathologic response after surgical resection. Pathological response was as follows: pCR (10/23 44%); pPR(13/23 56%). CTC grade 2 or 3 mucosistis occured in all pts. Hematologic toxicity was as follows: hemoglobin CTC grade 3 (14%), leukocytes CTC grade 1 (24%), grade 3 (33%), grade 4 (10%), thrombocytes CTC grade 2 (10%), grade 3(14%).
Conclusions: Concurrent P/C and radiotherapy resulted in excellent clinical and pathological response rates in advanced stage disease. Mucositis was the most common and significant toxicity.

Keywords: Paclitaxel, Carboplatin, phase-II-clinical-trial, head and neck cancer, squamous cell carcinoma, chemotherapy, radiotherapy, Dösak

Conference/Exhibition:
3. - 23.03.2000
24. Deutscher Krebskongress
Berlin